Melvine's AI Analysis # 44 -AI in the Lab: How Novartis is Rewriting the Rules of Drug Discovery

Artificial Intelligence (AI) and Generative AI (Gen AI) are rapidly reshaping industries globally, with healthcare and pharmaceuticals among the most profoundly transformed sectors. Novartis, a leading global pharmaceutical company, has emerged as a frontrunner in harnessing AI capabilities to drive innovation, enhance operational efficiency, and revolutionize patient care. This article explores Novartis’s AI and Gen AI initiatives, industry trends, competitor strategies, anticipated impacts, inherent risks, challenges, and the evolving regulatory landscape.